Chronic Heart Failure (CHF)NCT06248658
Assessment of the Impact of Clinical Decision Support Systems Included in Electronic Health Records
An observational study of Chronic Heart Failure (CHF), run by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation at 1 site in Russia.
Trial summary
A non--interventional study to assess the impact of clinical decision support systems included in electronic health records on compliance with guidelines, including routing of patients with CHF, follow-up care, prescription and dose titration of medicinal products. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Heart Failure (CHF)
- How many people
- 66,166 participants
- Where
- 1 siteRussia
- Study dates
- 1 Oct 2023to 31 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Currently, all regional health clinics use the regional HIS to collect clinical data on patients of very high-risk groups based on the data of electronic health records. It is expected that the current study will include patients being in follow-up care, with a history of cerebrovascular accident, myocardial infarction and coronary artery bypass grafting, Arterial angioplasty with stenting and catheter ablation for CVD, within 2 years after the diagnosis date
Who may be able to join
- Any cardiac diagnosis ICD-10 codes I00-I99
- Age: ≥18 years
- CHF stage 2a and higher and/or FC II and higher
- The data export for analysis is carried out through obtaining the structured electronic healthcare records (SHCR) from the Vertically Integrated Medical Information System "Cardiovascular Diseases" (VIMIS CVD). Such export implies obtaining documents of patients with IHD, ACS, CVA, AF and CHF, occlusion and stenosis of carotid artery, infective endocarditis and cardiac device-related endocarditis, which are sent by the region to VIMIS CVD.
Who cannot join
- 1. Age: <18 years
Trial locations and contacts
1 site in 1 country.
Russia1 site
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Moscow
About this study
Official title: A Non-interventional Study to Assess the Impact of Clinical Decision Support Systems Included in Electronic Health Records on Compliance With Guidelines
A non--interventional study to assess the impact of clinical decision support systems included in electronic health records on compliance with guidelines, including routing of patients with CHF, follow-up care, prescription and dose titration of medicinal products.
Read the detailed description
Circulatory system diseases are the leading cause of death in the Russian Federation. Ischemic heart disease (IHD) constitutes the largest share of circulatory system disease mortality, and also among the active working age population. According to the Federal State Statistics Service, IHD accounts for 54.2% in the structure of circulatory system disease mortality in the Russian Federation in 2020.
One of the most hazardous components of IHD is acute coronary syndrome (ACS). It is ACS that is one of the most common causes of CHD. In Russia, about 520,000 cases of ACS are recorded annually.
Chronic heart failure (CHF) is at the end of the cardiovascular disease continuum, which is characterized by a significant increase in overall and cardiovascular mortality risks. Therefore, a poor prognosis in this patient population, a high frequency of hospitalizations and a steady increase in the number of patients due to the population aging make CHF one of the priority areas for modern cardiology.
The most common cause of CHF is myocardial infarction. And, on the other hand, in about 20% of cases, acute myocardial infarction (AMI) is complicated by CHF, despite the success of reperfusion therapy. This patient group requires special attention. The mortality rates in patients with MI and HF are more than 10 times greater than in patients with MI without HF.
According to the guidelines for CHF 2020 approved by the Scientific and Practical Council of the Ministry of Health of Russia, the average annual mortality rate among patients with I-IV FC CHF in the Russian Federation is 6%, while in patients with clinically significant CHF, it is 12%. According to the EPOCH study data, it is known that the total mortality risk in CHF of any functional class (FC) is more than 10 times greater compared to the total mortality risk in the population of respondents without CHF, and the average life expectancy in patients with I-II FC and III-IV FC CHF is 7.8 and 4.8 years, respectively. Therefore, the scientific community agrees that mortality in patients with CHF is still high, and the rates of decline are insufficient. Consequently, the need for strategy development to reduce the demographic and financial losses from CHF is recognized in many countries, and the issues of implementing new technologies to reduce the mortality rates among patients with CHF are being studied and widely discussed in the literature.
High comorbidity and numerous hospitalizations turn the patients with heart failure (HF) into "super consumers" of the healthcare system resources. Comorbid CHF makes the disease burden even greater. For example, patients with a double burden of CKD and CHF (the most common comorbid combination, 43.8%) demonstrate unacceptably high rates of symptom burden, hospitalization rates, and mortality. The adjusted survival probability in patients with CHF and CKD after 2 years is 77.8% compared to 93.7% in patients without CHF and CHD (difference: 15.9%). One of the studies of CHF comorbidity demonstrated that atrial fibrillation (AF) in highly comorbid patients (average number of disease areas per patient with CHF: 4.6 ± 1.6) was more common than in patients with low comorbidity (23.4% and 7.5% of cases, respectively; p = 0.007).
Existing innovative therapeutic approaches in combination with the introduction of components of the CHF patient service can significantly influence the prognosis and reduce the burden on the healthcare system. However, in real-world clinical practice in the Russian Federation, the percentage of patients with HF who receive innovative drug therapy and the frequency of achieving target doses of disease modifying therapies are still low.
To reduce the circulatory system disease mortality, the Government of the Russian Federation has developed and is implementing the Federal Project "Combating Cardiovascular Diseases" and regional programs under the same name. They include the Program for Preferential Drug Provision for patients with AMI, CVA, as well as if they had CABG, PCI, and RFA procedures within the first two years of follow-up care. Consequently, the importance of Digital Systems is increasing, since they help identify such patients and perform their therapy in full.
Possible reasons for the current situation include low effectiveness of organizational approaches, in particular, a low percentage of patients visiting outpatient facilities after discharge, non-compliance with follow-up care timing, extremely low frequency of laboratory tests and diagnostic procedures, including a test for NT-proBNP level.
Monitoring of key clinical parameters of CHF patients, given medical therapy, assessment of follow-up care effectiveness, evaluation of consumed healthcare system resources using electronic health records (EHR) is one of the effective approaches to better adherence of healthcare professionals (HCPs) to the Guidelines, improved quality of health care, which, in its turn, can help improve the prognosis and to achieve the target mortality rates in circulatory system diseases. However, despite the pronounced success in the fight against circulatory system diseases, including CHF, the use of EHR systems as a tool for assessing the effectiveness of HF patient management and collecting statistical data is still unexplored. The EHR systems, which are used for collection and analysis of data on HF patients, have been introduced by healthcare providers in several regions in the Russian Federation.
In this study, the implementation strategy involves provision HCPs (primary care physicians and cardiologists) with access to the service that allows analyzing the data on routing and key clinical parameters of CHF patients.
The primary objective of this study is to assess the effectiveness of the implementation of the CDSS (clinical decision support system) aimed at improving the HCP compliance with the main provisions of the guidelines for heart failure in real-world clinical practice in order to enhance the effectiveness of this patient category management and improve clinical outcomes in the pilot regions of the Russian Federation.
- Conditions
- Chronic Heart Failure (CHF)
- Keywords
- heart failure, clinical decision support systems, guidelines
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Inpatient cohort | Patients who were admitted to hospital for any cardiac diagnosis (ICD-10 codes I00-I99), with CHF of stage 2a or higher and/or FC II and higher as the primary or secondary (concomitant or as a complication) diagnosis. Index event is the earliest hospitalization for any cardiac diagnosis during which an ICD code I50.x (standard coding) and/or I11.0, I13.0, I13.2, I25.5, I42.0, I42.9, I09.9, I43.0, I43.1, I43.2, I43.8, I42.5, I42.6, I42.7, I42.8 (extended coding) is specified as a primary or secondary diagnosis, or the clinical diagnosis specify CHF of stage 2a or higher and/or FC II and higher, or according to the CDSS algorithm criteria, the patient's clinical presentation corresponds to CHF (a subcohort of patients included based on the diagnosis established by the CDSS is subject to an individual analysis). | |
| Outpatient cohort | Patients who had an outpatient visit for any cardiac diagnosis (ICD-10 codes I00-I99), with: 1) CHF of stage 2a or higher and/or FC II and higher as the primary or secondary (concomitant or as a complication) diagnosis at the same visit. Index event is the earliest outpatient visit to a general practitioner or cardiologist for any cardiac diagnosis for which an ICD code I50.x (standard coding) and/or I11.0, I13.0, I13.2, I25.5, I42.0, I42.9, I09.9, I43.0, I43.1, I43.2, I43.8, I42.5, I42.6, I42.7, I42.8 (extended coding) is specified as a primary or secondary diagnosis, or the clinical diagnosis specify CHF of stage 2a or higher and/or FC II and higher, or according to the CDSS algorithm criteria, the patient's clinical presentation corresponds to CHF of stage 2a or higher and/or FC II and higher (a subcohort of patients included based on the diagnosis established by the CDSS is subject to an individual analysis). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of patients who underwent BNP/NT-proBNP test and/or echocardiography basic diagnostic tests and, consequently, improved CHF detection rates
To assess the effectiveness of the CDSS implementation with regard to an increase in frequency of basic diagnostic tests and, consequently, improved CHF detection rates
For the inpatient cohort, the percentage will be calculated as the number of patients who underwent at least one of the above diagnostic tests or a combination of two criteria during the observation period, divided by the number of patients included in the inpatient cohort.
The percentages of patients who underwent each of the tests separately (BNP/NT-proBNP or EchoCG) are calculated separately.
For the outpatient cohort, the percentage will be calculated as the number of patients who underwent at least one of the above diagnostic tests or a combination of two criteria during the observation period, divided by the number of patients included in the outpatient cohort.
The percentages of patients who underwent each of the tests separately (BNP/NT-proBNP or EchoCG) are calculated separately.
Measured: 12 months
Secondary outcomes (18)
Assessment of the data in the EHR for the index event and for the last reported case of health care delivery during the follow-up.
- Percentage of patients with a record about left ventricular ejection fraction (LVEF), with specified CHF stage, with specified NYHA FC CHF
- Percentage of patients with HFrEF, HFmrEF, HFpEF
- Percentage distribution by CHF stages (of those with the specified stage), by NYHA FC CHF (of those with specified FC)
- Percentage of patients with a diagnosis code I50.x (standard coding) and/or I11.0, I13.0, I13.2, I25.5, I42.0, I42.9, I09.9, I43.0, I43.1, I43.2, I43.8, I42.5, I42.6, I42.7, I42.8 (extended coding)
- Percentage of patients depending on the diagnosis source
Measured: 12 months
The basic socio-demographic characteristics and lifestyle peculiarities in CHF patients (gender)
Gender (female, male): % Mean, min and max (where applicable)
Measured: 12 months
The performance of diagnostic procedures in the hospital setting (index hospitalization)
Physical diagnosis
- Percentage of patients with at least one parameter value in the discharge summary (Body weight, SBP/DBP, HR) Instrumental diagnostics
- Percentage of patients who underwent ECG, chest X-ray, echocardiography
- Percentage of patients with an ejection fraction specified in the discharge summary Laboratory diagnostics
- Percentage of patients who underwent a blood chemistry test in the hospital setting (Creatinine, eGFR in EHR, Potassium, Sodium, Bilirubin, ALT, AST)
- Percentage of patients who underwent BNP or NT-proBNP measurement; a complete blood count, an urinalysis in the hospital setting
Measured: 12 months
The recommended therapy at discharge
- Percentage of patients who were recommended at discharge (RAAS inhibitors (ACE inhibitors or ARBs or ARNI (sacubitril/valsartan), Separately for each class: ACE inhibitors, ARBs, ARNI (with a breakdown by INN according to the Guidelines), Beta blockers, MRA, iSGLT2, Diuretics, Ivabradine)
- Percentage of patients who were recommended specified or unspecified dosage, distribution by the level of the drug dose recommended at discharge (min, mean, therapeutic (max), unspecified dosage) (RAAS inhibitors (ACE inhibitors or ARBs or ARNI (sacubitril/valsartan), Beta blockers)
Measured: 12 months
The effectiveness of the CDSS implementation with regard to improvement in follow-up care
- Percentage of patients enrolled in CHF follow-up care
- Percentage of patients being in CHF care at the date of cohort follow-up completion.
- Percentage of patients whose EHRs contain all the necessary parameters to determine the specialist physician for follow-up care (functional class of angina, blood pressure, heart rate, levels of cholesterol, LDL-C, triglycerides, diabetes mellitus (DM), CKD, CKD stage, prescribed therapy)
- Percentage of patients with a correctly identified specialist physician (primary care physician/cardiologist) for CHF follow-up care
Measured: 12 months
The effectiveness of the CDSS implementation with regard to improvement in follow-up care and patient routing
- Percentage of patients who continued observation at the outpatient stage after discharge: at least one (first after discharge) visit to a primary care physician or cardiologist within 1 (2, 4, 6, 8) weeks after discharge
- Percentage of patients with 0, 1-2, 3-4, >4 outpatient visits to a primary care physician or cardiologist within 6/12 months after discharge
- Percentage of patients with 0, 1-2, 3-4,> 4 outpatient visits to a primary care physician or cardiologist within 6/12 months after the index event
Measured: 12 months
The effectiveness of the CDSS implementation with regard to the performance of examination at the outpatient stage
- Percentage of outpatient visits with an EHR entry (Body weight, SBP/DBP, HR, Swelling)
- Percentage of patients who had measurements at least at one outpatient visit (there is a record in the EHR)
Measured: 12 months
The effectiveness of the CDSS implementation with regard to improvement in the prescription and therapy continuity at the outpatient stage
- The percentage of patients who were prescribed/asked to continue medical therapy during the outpatient visit
- Percentage of patients (for the inpatient cohort) who, at the outpatient visit, had a change in the drug INN compared to the one recommended at discharge
- Percentage of patients whose therapy that was recommended at discharge was discontinued during an outpatient visit
- Percentage of patients whose therapy doses were escalated/reduced at outpatient visits compared to the dose level prescribed/recommended during hospitalization
- Percentage of patients whose therapy doses were escalated at outpatient visits
- Percentage of patients whose therapy doses were reduced at outpatient visits
- The percentage of patients who had any change in the dose of the medicinal product during outpatient visits
Measured: 12 months
The effectiveness of the CDSS implementation with regard to updating comorbidity in patients with CHF
- The percentage of patients with CHF and IHD, and separately CHF and MI / postinfarction cardiosclerosis, CHF and unstable angina, CHF and stable effort angina
- The percentage of patients with CHF and AH
- The percentage of patients with CHF and heart rhythm disorders (HRD)
- The percentage of patients with CHF and CVA (stroke, TIA, CVD)
- The percentage of patients with CHF and CKD
- The percentage of patients with CHF and type 2 DM
- The percentage of patients with 2, 3, and more comorbidities
- The percentage of patients with vascular interventions
Measured: 12 months
The effectiveness of the CDSS implementation with regard to improvement in clinical outcomes of patients with CHF
- Percentage, absolute number of cases, incidence of (cases per 100 patient-years) hospitalizations for cardiac diagnoses within 1/3/6/12 months after the index event by types HF: HFrEF, HFmrEF, HFpEF and with a breakdown by hospitalization cause: CHF, for MI (AMI / NSTE-ACS/NSTE-ACS), for IHD (unstable angina pectoris), TIA, CVA, stroke, for heart rhythm disorder (including AF), for other cardiac diseases (including uncontrolled hypertension), CKD (renal impairment).
- Percentage, absolute number, frequency (cases per 100 patient-years) of emergency calls during 3/6/12 months after the index event
- Percentage of telemedicine consultations after the index event in total and by EF in CHF.
Measured: 12 months
The effectiveness of the CDSS implementation with regard to monitoring the provision of patients with CHF
- Percentage of patients after AMI and CHF, CVA and CHF, CABG and CHF, PCI and CHF, RFA and CHF with a prescription for the treatment of CHF
- Percentage of patients receiving ARNI, iSGLT2, other therapy, in patients with HFrEF, HFmrEF, HFpEF
- Frequency of emergency calls by patients receiving the treatment of CHF being in follow-up care for 6 months/12 months
Measured: 12 months
Characteristic of blood pressure in patients with increased risks of CHF occurrence or its course
Systolic blood pressure (SBP) and diastolic blood pressure (DBP): mean +-SD, median, quartiles, min and max
Measured: 12 months
The effectiveness of the CDSS implementation with regard to improvement in follow-up care and patient routing per one patient-year
- The average number of outpatient visits per one patient-year of follow-up after the index event: number of visits to the primary care physician, cardiologist, separately, and in total
- The average number of outpatient visits per one patient-year of follow-up after discharge: number of visits to the primary care physician, cardiologist, separately, and in total.
Measured: 12 months
The effectiveness of the CDSS implementation with regard to the performance of diagnostic tests at the outpatient stage
-Percentage of patients who underwent the following tests over the analyzed period (Creatinine, eGFR (from EHR), BNP/NT-proBNP, Potassium, sodium, Bilirubin, ALT, AST, CBC (RBCs, Hb), ECG, Chest X-ray, EchoCG, Holter monitoring
Measured: 12 months
Characteristic of heart rate in patients with increased risks of CHF occurrence or its course
-HR (mean, +-SD, median, min and max quartiles)
Measured: 12 months
Characteristic of lipid profile and laboratory tests in patients with increased risks of CHF occurrence or its course
-Lipid profile (total cholesterol, LDL-C, HDL-C, VLDL-C, non-HDL-C, triglycerides, Lp(a)) as well as glucose, HbA1, creatinine, ALT, AST, Hb (Note: if several test results are available, the closest to the index date will be selected
Measured: 12 months
The basic socio-demographic characteristics and lifestyle peculiarities in CHF patients (age)
Age (years): % Mean, min and max (where applicable)
Measured: 12 months
The basic socio-demographic characteristics and lifestyle peculiarities in CHF patients (Weight, BMI)
Body weight (kg), height (m), body mass index (kg/m2) Weight and height will be combined to report BMI in kg/m2.
% Mean, min and max (where applicable)
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Feb 2024
- Study start1 Oct 2023
- Primary completion28 Feb 2025
- Study completion31 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Heart Failure (CHF)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 66,166 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Sponsor type
- Other government
- Collaborators
- National Society for the Study of Heart Failure and Myocardial Diseases, Novartis
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06248658
- Sponsor's protocol ID
- 20240122
- Status last verified
- Apr 2026
- First submitted
- 22 Jan 2024
- Last updated
- 17 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Non-interventional Study to Assess the Impact of Clinical Decision Support Systems Included in Electronic Health Records on Compliance With Guidelines
- ClinicalTrials.gov ID
- NCT06248658
- Acronym / sponsor ID
- 20240122
- Conditions
- Chronic Heart Failure (CHF)
- Keywords
- heart failure, clinical decision support systems, guidelines
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 66,166 participants (actual)
- Lead sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian FederationOther government
- Collaborators
- National Society for the Study of Heart Failure and Myocardial Diseases, Novartis
- Study start
- 1 Oct 2023 (actual)
- Primary completion
- 28 Feb 2025 (actual)
- Study completion
- 31 May 2025 (actual)
- First posted
- 8 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A non--interventional study to assess the impact of clinical decision support systems included in electronic health records on compliance with guidelines, including routing of patients with CHF, follow-up care, prescription and dose titration of medicinal products.
Detailed description
Circulatory system diseases are the leading cause of death in the Russian Federation. Ischemic heart disease (IHD) constitutes the largest share of circulatory system disease mortality, and also among the active working age population. According to the Federal State Statistics Service, IHD accounts for 54.2% in the structure of circulatory system disease mortality in the Russian Federation in 2020.
One of the most hazardous components of IHD is acute coronary syndrome (ACS). It is ACS that is one of the most common causes of CHD. In Russia, about 520,000 cases of ACS are recorded annually.
Chronic heart failure (CHF) is at the end of the cardiovascular disease continuum, which is characterized by a significant increase in overall and cardiovascular mortality risks. Therefore, a poor prognosis in this patient population, a high frequency of hospitalizations and a steady increase in the number of patients due to the population aging make CHF one of the priority areas for modern cardiology.
The most common cause of CHF is myocardial infarction. And, on the other hand, in about 20% of cases, acute myocardial infarction (AMI) is complicated by CHF, despite the success of reperfusion therapy. This patient group requires special attention. The mortality rates in patients with MI and HF are more than 10 times greater than in patients with MI without HF.
According to the guidelines for CHF 2020 approved by the Scientific and Practical Council of the Ministry of Health of Russia, the average annual mortality rate among patients with I-IV FC CHF in the Russian Federation is 6%, while in patients with clinically significant CHF, it is 12%. According to the EPOCH study data, it is known that the total mortality risk in CHF of any functional class (FC) is more than 10 times greater compared to the total mortality risk in the population of respondents without CHF, and the average life expectancy in patients with I-II FC and III-IV FC CHF is 7.8 and 4.8 years, respectively. Therefore, the scientific community agrees that mortality in patients with CHF is still high, and the rates of decline are insufficient. Consequently, the need for strategy development to reduce the demographic and financial losses from CHF is recognized in many countries, and the issues of implementing new technologies to reduce the mortality rates among patients with CHF are being studied and widely discussed in the literature.
High comorbidity and numerous hospitalizations turn the patients with heart failure (HF) into "super consumers" of the healthcare system resources. Comorbid CHF makes the disease burden even greater. For example, patients with a double burden of CKD and CHF (the most common comorbid combination, 43.8%) demonstrate unacceptably high rates of symptom burden, hospitalization rates, and mortality. The adjusted survival probability in patients with CHF and CKD after 2 years is 77.8% compared to 93.7% in patients without CHF and CHD (difference: 15.9%). One of the studies of CHF comorbidity demonstrated that atrial fibrillation (AF) in highly comorbid patients (average number of disease areas per patient with CHF: 4.6 ± 1.6) was more common than in patients with low comorbidity (23.4% and 7.5% of cases, respectively; p = 0.007).
Existing innovative therapeutic approaches in combination with the introduction of components of the CHF patient service can significantly influence the prognosis and reduce the burden on the healthcare system. However, in real-world clinical practice in the Russian Federation, the percentage of patients with HF who receive innovative drug therapy and the frequency of achieving target doses of disease modifying therapies are still low.
To reduce the circulatory system disease mortality, the Government of the Russian Federation has developed and is implementing the Federal Project "Combating Cardiovascular Diseases" and regional programs under the same name. They include the Program for Preferential Drug Provision for patients with AMI, CVA, as well as if they had CABG, PCI, and RFA procedures within the first two years of follow-up care. Consequently, the importance of Digital Systems is increasing, since they help identify such patients and perform their therapy in full.
Possible reasons for the current situation include low effectiveness of organizational approaches, in particular, a low percentage of patients visiting outpatient facilities after discharge, non-compliance with follow-up care timing, extremely low frequency of laboratory tests and diagnostic procedures, including a test for NT-proBNP level.
Monitoring of key clinical parameters of CHF patients, given medical therapy, assessment of follow-up care effectiveness, evaluation of consumed healthcare system resources using electronic health records (EHR) is one of the effective approaches to better adherence of healthcare professionals (HCPs) to the Guidelines, improved quality of health care, which, in its turn, can help improve the prognosis and to achieve the target mortality rates in circulatory system diseases. However, despite the pronounced success in the fight against circulatory system diseases, including CHF, the use of EHR systems as a tool for assessing the effectiveness of HF patient management and collecting statistical data is still unexplored. The EHR systems, which are used for collection and analysis of data on HF patients, have been introduced by healthcare providers in several regions in the Russian Federation.
In this study, the implementation strategy involves provision HCPs (primary care physicians and cardiologists) with access to the service that allows analyzing the data on routing and key clinical parameters of CHF patients.
The primary objective of this study is to assess the effectiveness of the implementation of the CDSS (clinical decision support system) aimed at improving the HCP compliance with the main provisions of the guidelines for heart failure in real-world clinical practice in order to enhance the effectiveness of this patient category management and improve clinical outcomes in the pilot regions of the Russian Federation.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Inpatient cohort | – | –Patients who were admitted to hospital for any cardiac diagnosis (ICD-10 codes I00-I99), with CHF of stage 2a or higher and/or FC II and higher as the primary or secondary (concomitant or as a complication) diagnosis. Index event is the earliest hospitalization for any cardiac diagnosis during which an ICD code I50.x (standard coding) and/or I11.0, I13.0, I13.2, I25.5, I42.0, I42.9, I09.9, I43.0, I43.1, I43.2, I43.8, I42.5, I42.6, I42.7, I42.8 (extended coding) is specified as a primary or secondary diagnosis, or the clinical diagnosis specify CHF of stage 2a or higher and/or FC II and higher, or according to the CDSS algorithm criteria, the patient's clinical presentation corresponds to CHF (a subcohort of patients included based on the diagnosis established by the CDSS is subject to an individual analysis). |
| Outpatient cohort | – | –Patients who had an outpatient visit for any cardiac diagnosis (ICD-10 codes I00-I99), with: 1) CHF of stage 2a or higher and/or FC II and higher as the primary or secondary (concomitant or as a complication) diagnosis at the same visit. Index event is the earliest outpatient visit to a general practitioner or cardiologist for any cardiac diagnosis for which an ICD code I50.x (standard coding) and/or I11.0, I13.0, I13.2, I25.5, I42.0, I42.9, I09.9, I43.0, I43.1, I43.2, I43.8, I42.5, I42.6, I42.7, I42.8 (extended coding) is specified as a primary or secondary diagnosis, or the clinical diagnosis specify CHF of stage 2a or higher and/or FC II and higher, or according to the CDSS algorithm criteria, the patient's clinical presentation corresponds to CHF of stage 2a or higher and/or FC II and higher (a subcohort of patients included based on the diagnosis established by the CDSS is subject to an individual analysis). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Currently, all regional health clinics use the regional HIS to collect clinical data on patients of very high-risk groups based on the data of electronic health records. It is expected that the current study will include patients being in follow-up care, with a history of cerebrovascular accident, myocardial infarction and coronary artery bypass grafting, Arterial angioplasty with stenting and catheter ablation for CVD, within 2 years after the diagnosis date
Key inclusion criteria (4 listed)
- Any cardiac diagnosis ICD-10 codes I00-I99
- Age: ≥18 years
- CHF stage 2a and higher and/or FC II and higher
- The data export for analysis is carried out through obtaining the structured electronic healthcare records (SHCR) from the Vertically Integrated Medical Information System "Cardiovascular Diseases" (VIMIS CVD). Such export implies obtaining documents of patients with IHD, ACS, CVA, AF and CHF, occlusion and stenosis of carotid artery, infective endocarditis and cardiac device-related endocarditis, which are sent by the region to VIMIS CVD.
Key exclusion criteria (1 listed)
- 1. Age: <18 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of patients who underwent BNP/NT-proBNP test and/or echocardiography basic diagnostic tests and, consequently, improved CHF detection rates
Time frame: 12 months
To assess the effectiveness of the CDSS implementation with regard to an increase in frequency of basic diagnostic tests and, consequently, improved CHF detection rates For the inpatient cohort, the percentage will be calculated as the number of patients who underwent at least one of the above diagnostic tests or a combination of two criteria during the observation period, divided by the number of patients included in the inpatient cohort. The percentages of patients who underwent each of the tests separately (BNP/NT-proBNP or EchoCG) are calculated separately. For the outpatient cohort, the percentage will be calculated as the number of patients who underwent at least one of the above diagnostic tests or a combination of two criteria during the observation period, divided by the number of patients included in the outpatient cohort. The percentages of patients who underwent each of the tests separately (BNP/NT-proBNP or EchoCG) are calculated separately.
18 secondary outcomes
Assessment of the data in the EHR for the index event and for the last reported case of health care delivery during the follow-up.
Time frame: 12 months
The basic socio-demographic characteristics and lifestyle peculiarities in CHF patients (gender)
Time frame: 12 months
The performance of diagnostic procedures in the hospital setting (index hospitalization)
Time frame: 12 months
The recommended therapy at discharge
Time frame: 12 months
The effectiveness of the CDSS implementation with regard to improvement in follow-up care
Time frame: 12 months
The effectiveness of the CDSS implementation with regard to improvement in follow-up care and patient routing
Time frame: 12 months
The effectiveness of the CDSS implementation with regard to the performance of examination at the outpatient stage
Time frame: 12 months
The effectiveness of the CDSS implementation with regard to improvement in the prescription and therapy continuity at the outpatient stage
Time frame: 12 months
The effectiveness of the CDSS implementation with regard to updating comorbidity in patients with CHF
Time frame: 12 months
The effectiveness of the CDSS implementation with regard to improvement in clinical outcomes of patients with CHF
Time frame: 12 months
The effectiveness of the CDSS implementation with regard to monitoring the provision of patients with CHF
Time frame: 12 months
Characteristic of blood pressure in patients with increased risks of CHF occurrence or its course
Time frame: 12 months
The effectiveness of the CDSS implementation with regard to improvement in follow-up care and patient routing per one patient-year
Time frame: 12 months
The effectiveness of the CDSS implementation with regard to the performance of diagnostic tests at the outpatient stage
Time frame: 12 months
Characteristic of heart rate in patients with increased risks of CHF occurrence or its course
Time frame: 12 months
Characteristic of lipid profile and laboratory tests in patients with increased risks of CHF occurrence or its course
Time frame: 12 months
The basic socio-demographic characteristics and lifestyle peculiarities in CHF patients (age)
Time frame: 12 months
The basic socio-demographic characteristics and lifestyle peculiarities in CHF patients (Weight, BMI)
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Chronic Heart Failure (CHF)
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Not yet recruiting
Community Health Worker Nutrition Self-Management Support for Cardio-Kidney-Metabolic Health
Hypertension (HTN), CKD - Chronic Kidney Disease
RecruitingPhase 4
The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency
Heart Failure, Iron Deficiency
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
RecruitingObservational study
Norepinephrine in the Management of General Anesthesia-Induced Arterial Hypotension in Chronic Heart Failure Patients
Hypotension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Heart Failure (CHF), run by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of patients who underwent BNP/NT-proBNP test and/or echocardiography basic diagnostic tests and, consequently, improved CHF detection rates (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2026.